"10.1371_journal.pone.0067264","plos one","2013-06-28T00:00:00Z","Klaus Martiny; Else Refsgaard; Vibeke Lund; Marianne Lunde; Lene SÃ¸rensen; Britta Thougaard; Lone Lindberg; Per Bech","Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Psychiatric Research Unit, Mental Health Centre North Zealand, Copenhagen University Hospital, Copenhagen, Denmark; Child and Adolescent Psychiatric Centre, Bispebjerg, Copenhagen University Hospital, Copenhagen, Denmark","Conceived and designed the experiments: KM ER VL ML LS BT LL PB. Performed the experiments: KM ER VL ML LS BT LL PB. Analyzed the data: KM ER VL ML LS BT LL PB. Contributed reagents/materials/analysis tools: KM ER VL ML LS BT LL PB. Wrote the paper: KM ER VL ML LS BT LL PB.","We have the following interests: This study received financial support and duloxetine from Eli Lilly, Copenhagen Denmark (https://www.eli-lilly.dk/), and AstraZeneca, Copenhagen, Denmark provided funding for a travel grant. Duloxetine is manufactured and marketed by Eli Lilly. Klaus Martiny has had part of his salary for working with the study paid by funding from Eli Lilly, Denmark and has occasionally served as a speaker for pharmaceutical companies with an interest in the drug treatment of affective disorders (Servier and Eli Lilly). Else Refsgaard has had part of her salary for working with the study paid by funding from Eli Lilly Denmark. Per Bech, until August 2008, occasionally received funding from and was a speaker or member of advisory boards for pharmaceutical companies with an interest in the drug treatment of affective disorders (Astra-Zeneca, Lilly, H Lundbeck A/S, and Organon). There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","06","Klaus Martiny","KM",8,TRUE,8,8,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
